SCHEMBL5669934

SCHEMBL5669934

CC(C)C(CS(=O)(=O)N1CCC(c2ccc(Cl)cc2Cl)CC1)C(=O)NO

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.41
CNR2 P34972 3/20 0.41
MMP1 P03956 1/20 0.40
GRM5 P41594 1/20 0.39
SLC6A9 P48067 3/20 0.39
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
OPRL1 P41146 1/20 0.38
MC4R P32245 2/20 0.37
MC5R P33032 1/20 0.37
MC3R P41968 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5669936 1.00 CNR1 (0.41) CNR1CNR2MMP1GRM5SLC6A9
SCHEMBL5670318 0.88 ADAM17 (0.45) MMP1TP53PTGDR2KMT2A
SCHEMBL5669604 0.88 MMP2 (0.41) MMP1LMNATP53MAPTL3MBTL1
SCHEMBL5669731 0.81 ADAM10 (0.48) TP53OPRL1PTGDR2
SCHEMBL5669746 0.81 GRM5 (0.37) CNR1CNR2GRM5SLC6A9LMNA
SCHEMBL5669744 0.81 GRM5 (0.37) CNR1CNR2GRM5SLC6A9LMNA
SCHEMBL5670613 0.80 ADAM10 (0.46) MMP1MAPTKMT2ANPSR1ALDH1A1
SCHEMBL5670609 0.80 ADAM10 (0.46) MMP1MAPTKMT2ANPSR1ALDH1A1
SCHEMBL5671594 0.79 ADAM10 (0.45) MMP1ALDH1A1
SCHEMBL5670514 0.79 ADAM10 (0.45) MMP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-12-07 US disclosed
EP-1648868-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R&D LTD (GB) 2006-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276507-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD2, CD22, NEU3 CNR1 2818/4885CNR2 1845/4885MMP1 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.